

Co-Arinate®

artesunate, sulfamethoxypyrazine, pyrimethamine

CURATIVE ACT TREATMENT

- ✓ **Fixed Dose Combination**
- ✓ **Full treatment: only 3 tabs**

Presentation	Weight in kg (age in years)	Number of tablets			
		0 h	24 h	48 h	Total course
Co-Arinate® junior	≥ 10kg ≤ 18kg (1 – 5 years)	1/2	1/2	1/2	1,5 tablets
	≥ 18kg ≤ 36kg (6 – 13 years)	1	1	1	3 tablets
Co-Arinate® adult	≥ 36kg ≤ 80kg (> 14 years and adults)	1	1	1	3 tablets

**Dafra Pharma International
Headquarters**

Slachthuisstraat 30/7
2300 Turnhout - Belgium

Co-Arinate®

artesunate, sulfamethoxyprazine & pyrimethamine



CURATIVE ACT TREATMENT

Fixed dose that combines observance, efficacy and safety in a 3 day treatment



A REMARKABLE PROGRESS
IN THE TREATMENT OF MALARIA



Setting the standard

www.dafrapharma.com

Co-Arinate®

artesunate,
sulfamethoxyprazine,
pyrimethamine



Co-Arinate® contains three medicaments active against malaria parasites. Malaria cure can be obtained within 48 hours. In this combination the drug Artesunate kills the parasites very fast and potentiates the effects of the other two drugs Sulfamethoxyprazine and Pyrimethamine which have a long elimination half-life. This combination therapy permits a shorter duration of treatment, thereby improving compliance. The theoretical risk for drug resistance is significantly reduced by using combination therapy.

IDENTIFICATION OF PRODUCT

What is in the medicine?

Co-Arinate® contains three active ingredients called Artesunate, Sulfamethoxyprazine and Pyrimethamine.

Excipients: maltodextrin, microcrystalline cellulose, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate.

Presentation

Box containing 1 blister of 3 tablets.

There are two qualitative and quantitative compositions available:

1) Co-Arinate® adult:

Each tablet contains 200 mg Artesunate, 500 mg Sulfamethoxyprazine and 25 mg Pyrimethamine.

2) Co-Arinate® junior:

Each tablet contains 100 mg Artesunate, 250 mg Sulfamethoxyprazine and 12.5 mg Pyrimethamine.

Pharmacotherapeutical class

Antimalarial drug.

PROPERTIES

Artesunate is a very active derivative of the Artemisinins, a new class of antimalarial drugs derived from Artemisinin. The latter compound is extracted from the plant *Artemisia Annua* and Artesunate is prepared semi-synthetically. Sulfamethoxyprazine is a long-acting sulphonamide that acts as a folic acid biosynthesis inhibitor. Pyrimethamine is also a folic acid biosynthesis antagonist (reductase inhibitor).

USE/INDICATION

Co-Arinate® is used as curative treatment for all forms of malaria, including severe malaria caused by multi drug-resistant strains of *Plasmodium falciparum*. In case of *P. vivax* addition of primaquine may be required.

DOSAGE AND METHODS OF ADMINISTRATION

Co-Arinate® has been especially designed to treat malaria in 48 hours in children, adolescents and adults.

In general

4 mg Artesunate/kg body weight in combination with Sulfamethoxyprazine and Pyrimethamine. Three consecutive intakes of this dose must be given during 48 hours; one dose at time 0 followed by a second and a third dose after 24 hours and 48 hours, respectively (dose interval 24 hours).

Note:

A full course therapy is essential in order to avoid recrudescence. In case of vomiting within 30 minutes after intake of the tablet, the full dose should be re-administered. Vomiting within 1 hour requires repeating half the dose.

Dosage scheme

Daily dose = 4 mg of Artesunate x Body weight of the patient

Compositions = Co-Arinate® junior
Co-Arinate® adult

Presentation	Weight in kg (age in years)	Number of tablets			
		0 h	24 h	48 h	Total course
Co-Arinate® enfant	≥ 10kg ≤ 18kg (1-5 years)	1/2	1/2	1/2	1,5 tablets
	≥ 18kg ≤ 36kg (6-13 years)	1	1	1	3 tablets
Co-Arinate® adulte	≥ 36kg ≤ 80kg (> 14 years and adults)	1	1	1	3 tablets

Further dose adaptations may be necessary for adults > 80 kg and for obese patients. The tablets should normally be taken with fluid such as drinking water and they may be broken or crushed for convenience sake.

What to do in case of overdose?

The recommended dose should not be exceeded. In case of accidental over-dosage, symptomatic treatment in a specialised hospital setting is required. However, accidental doubling of the dose will in general not create side effects.

Additional information

A further course of Co-Arinate® may be necessary if the malaria infection returns (relapse) or if you are reinfected with Plasmodium parasites after having been cured.

UNDESIRE EFFECTS

The disease is characterised by unpleasant symptoms and these should not be confused with side effects of the drug. In general there are no side effects with this medication. Undesirable effects from Artesunate are generally rare at the therapeutic dose. In very rare cases, slight changes in haematologic values have been seen, including a reduction in the number of reticulocytes as well as a slight increase in transaminases. These signs however, do not generally give rise to any noticeable clinical manifestations. In rare cases, a slight, but transient reduction in sinus heart rate has been observed, and the QTc interval is not affected.

Abdominal cramps and mild diarrhoea have been reported at elevated doses, these symptoms are transient. Side effects with Sulfamethoxyprazine are extremely rare and the syndrome of Stevens-Johnson or the syndrome of Lyell have never been described. In theory, the syndrome of Stevens-Johnson or the syndrome of Lyell may occur although this has not been reported to date. Crystalluria due to the use of Sulfamethoxyprazine does not occur because of the excellent solubility of the parent compound and its acetylated metabolite.

WARNINGS AND CONTRAINDICATIONS

Before taking this medication

In case other medicines are taken or other medical problems are present, mention it to the doctor.

Contra-indications

Co-Arinate® is contra-indicated in individuals hypersensitive to Artesunate, Sulfa-methoxyprazine, Pyrimethamine or any of the other ingredients of this medication. The use of this medicine is

contra-indicated in case of severe hepatic or renal insufficiency and in case of severe blood dyscrasias or documented megaloblastic anaemia due to folic acid deficiency.

Interactions with other medicinal products

Artesunate

No clinically significant adverse drug interactions with Artesunate have been reported to date.

The activity of other anti-malaria drugs may be potentiated by Artesunate.

Sulfamethoxyprazine and Pyrimethamine

Antifolic acid drugs such as other sulfonamides or trimethoprim-sulfamethoxazole combinations should not be used while the patient is receiving Sulfamethoxyprazine in combination with Pyrimethamine (Co-Arinate®) for antimalarial treatment.

Pregnancy – Breastfeeding

Pregnancy

Use of the product is not recommended during the first trimester (organogenesis period) unless, in the doctor's opinion, the benefits outweigh the risks, as is often encountered with complicated and cerebral malaria. No cases of human embryotoxicity or teratogenicity have been reported.

Breastfeeding

Women should not breast feed their infants during Co-Arinate® therapy.

Sulfamethoxyprazine and Pyrimethamine are both excreted into maternal milk. Artesunate does not appear in the breast milk of lactating mothers, and its metabolite Dihydroartemisinin is present in minimum trace amounts.

Driving and using machines

No reactions are noted to date.

Special warnings

It is essential for patients to complete the full 24 hours of treatment to avoid recrudescence. In case of complicated malaria, general medical supportive care should be provided to the patient.

PHARMACEUTICAL PRECAUTIONS

Store below 30°C, in the original package, protected from light and humidity. Keep out of reach and sight of children. Do not use after the expiry date, stated on the packaging (Exp.). The expiry date refers to the last day of that month.